CasePit
AAPLTSLAMSFTNVDAAMZNGOOGLMETAAMDNFLXPLTRCOINJPM
AAPLTSLAMSFTNVDAAMZNGOOGLMETAAMDNFLXPLTRCOINJPM
Post DDLog in
  • Feed
  • Discover
  • Watchlist
  • Messages
  • Profile

Verify your position

Show a βœ“ badge on your posts. Proof beats opinion.

Add a position

Trending now

Promoted

Something missing?

s/wishlist is where features get requested, argued over, and built.

Open s/wishlist β†’

Not financial advice. Prices are delayed. Verified positions reflect a point-in-time check, not current holdings.

CasePit is a community discussion platform. Nothing here is financial advice, an offer, or a recommendation to buy or sell any security. Verified positions show what a member held at the time of verification, not what they hold now. Prices are delayed and provided for information only. Do your own research.

πŸ“± CasePit for iOS is in the works.

  • About
  • Congress
  • Insiders
  • Terms of Service
  • Privacy Policy
  • Risk Notice
  • Imprint
  • Moderation notices
  • Feed
  • Discover
  • +
  • Watchlist
  • Profile

MRK

Merck & Company, Inc.

Open
High
Low
Prev close
Volume

About Merck & Company, Inc.

Merck & Company, Inc. (MRK) is a Healthcare company in the Pharmaceutical Preparations industry with a market capitalisation of $358.8B. The stock trades at 116.30x trailing earnings and yields 2.34%.

Sector
Healthcare
Industry
Pharmaceutical Preparations
Market cap
$358.8B
P/E ratio
116.30
EPS (TTM)
$7.28
Revenue (TTM)
$65B
Free cash flow
$12.4B
Profit margin
28.1%
Dividend yield
2.34%
Shares outstanding
2.5B

Financial health: Strong8.3/10

6 strengths, 0 concerns. No red flags against these benchmarks.

  • Debt to equity: 0.94 (Watch, benchmark < 0.5) β€” Debt of 0.94x equity is moderate against the 0.5x benchmark. It has deteriorated over the last 4 years.
  • Net debt vs cash flow: 2.8y (Strong, benchmark < 4 years) β€” Net debt of $34.7B is 2.8x annual free cash flow β€” about 3 years of cash flow to repay.
  • Current ratio: 1.54 (Strong, benchmark > 1.5) β€” Short-term assets cover 1.54x short-term liabilities, against Graham's 1.5x floor. It has been broadly flat over the last 4 years.
  • Return on equity: 34.7% (Strong, benchmark > 15%) β€” Earns 34.7% on shareholder equity, comfortably past the > 15% mark.
  • Gross margin: 73.0% (Strong, benchmark > 40%) β€” Keeps 73.0% of revenue after the direct cost of sales, comfortably past the > 40% mark.
  • Net margin: 28.1% (Strong, benchmark > 10%) β€” Turns 28.1% of revenue into profit, comfortably past the > 10% mark.
  • Free cash flow: $12.4B (Strong, benchmark positive) β€” Generated $12.4B of free cash flow after capital spending. It has deteriorated over the last 4 years.
  • Revenue growth: 1.3% (Watch, benchmark > 10%) β€” Revenue changed 1.3% year on year, short of the > 10% mark.
  • Earnings growth: 6.6% (Watch, benchmark > 10%) β€” Earnings changed 6.6% year on year, short of the > 10% mark.

AI take

AI-generated Β· not financial advice

MRK news

Promoted

Something missing?

s/wishlist is where features get requested, argued over, and built.

Open s/wishlist β†’

Discussion in s/MRK